Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Retained Earnings: 2019-2025

Historic Retained Earnings for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to -$276.9 million.

  • Pharming Group N.V's Retained Earnings rose 0.54% to -$276.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$276.9 million, marking a year-over-year increase of 0.54%. This contributed to the annual value of -$275.5 million for FY2024, which is 3.86% down from last year.
  • Latest data reveals that Pharming Group N.V reported Retained Earnings of -$276.9 million as of Q3 2025, which was up 3.20% from -$286.0 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Retained Earnings ranged from a high of $3.4 million in Q4 2021 and a low of -$292.8 million during Q1 2025.
  • In the last 3 years, Pharming Group N.V's Retained Earnings had a median value of -$276.9 million in 2025 and averaged -$275.2 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first skyrocketed by 99.91% in 2022, then plummeted by 108,246.49% in 2023.
  • Over the past 5 years, Pharming Group N.V's Retained Earnings (Quarterly) stood at $3.4 million in 2021, then tumbled by 356.97% to -$8.7 million in 2022, then crashed by 2,936.08% to -$265.3 million in 2023, then fell by 3.86% to -$275.5 million in 2024, then rose by 0.54% to -$276.9 million in 2025.
  • Its last three reported values are -$276.9 million in Q3 2025, -$286.0 million for Q2 2025, and -$292.8 million during Q1 2025.